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Methods: The effects of hASCs on collagen-reactive RA human T cell proliferation and cytokine production were investigated, as well as effects on the production of inflammatory mediators by monocytes and fibroblast-like synoviocytes from patients with RA.
Results: hASCs suppressed the antigen-specific response of T cells from patients with RA. hASCs inhibited the proliferative response and the production of inflammatory cytokines by collagen-activated CD4 and CD8 T cells. In contrast, the numbers of IL10-producing T cells and monocytes were significantly augmented upon hASC treatment. The suppressive activity of hASCs was cell-tocell contact dependent and independent. hASCs also stimulated the generation of FoxP3 protein-expressing CD4 + CD25 + regulatory T cells, with the capacity to suppress collagen-specific T cell responses. Finally, hASCs downregulated the inflammatory response and the production of matrix-degrading enzymes by synovial cells isolated from patients with RA. Conclusions: The present work identifies hASCs as key regulators of immune tolerance, with the capacity to suppress T cell and inflammatory responses and to induce the generation/activation of antigen-specific regulatory T cells.
Adaptive immune response is carried out by a complex biological network of cells and molecular signals that relies on the discrimination between self and non-self antigens to protect the organism against a broad range of infectious agents while avoiding the development of misguided or excessive immune reactions, such as autoimmune and allergic reactions. The induction and maintenance of immunological self-tolerance seems to depend on the deletion of self-reactive clones during development and the generation/activation of regulatory T cells (Tr) in the periphery during adult life. 1 Understanding the mechanisms and factors involved in the generation or activation of Tr cells is a major challenge in immunology and medicine.
The initial stages of rheumatoid arthritis (RA) involve multiple steps, which can be divided into two main phases: initiation and establishment of autoimmunity to collagen-rich joint components, and later events associated with the evolving immune and inflammatory responses.
2 Certain therapeutic approaches address the self-reactive T cell component of RA, complementing existing therapies directed toward diminishing the inflammatory response. However, current therapies fail to completely arrest disease progression. In this sense, enhancement of the function of the Tr component could represent a valuable therapeutic strategy for RA. 1 3 Mesenchymal stem cells (MSCs) are resident mesoderm-derived stromal cells that function as precursors of non-haematopoietic connective tissues with capacity to differentiate into mesenchymal and non-mesenchymal cell lineages. 4 Besides their potential clinical application in tissue repair, bone marrow-derived MSCs (BM-MSCs) have been recently described as potent immunomodulators in various immune disorders. [4] [5] [6] [7] [8] Apart from BM-MSCs, other major sources of human MSCs are umbilical cord blood, peripheral blood and adipose tissue. Based on their accessibility, human adipose-derived MSCs (hASCs) have lately emerged as attractive alternatives for cell therapy. ASCs exert profound immunomodulatory properties and protective effects on acute graft versus host disease and experimental arthritis. 5 8-10 Here, we characterise the immunosuppressant activity of hASCs on collagen-reactive T cells and synovial cells from patients with RA.
METHODS

Cell isolation
To obtain hASCs, lipoaspirates obtained from adipose tissue from healthy subjects were digested with 0.075% type I collagenase (37uC, 30 min) and erythrocyte depleted with 160 mM ClNH 4 .
5 Cells (2-3610 4 /cm 2 ) were expanded in complete medium (Dulbecco modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mM glutamine and 1% penicillin/streptomycin) at 37uC and 5% CO 2 , changing the culture medium every 3-4 days. A total of 6 different samples with population doublings 6-9 were used in the study. These cells showed a fibroblast-like morphology and differentiation capacity to the adipocytic and osteocytic lineages, and expressed the phenotype HLA-DR 11 had clinically active synovitis and received no treatment or were treated only with non-steroidal antiinflammatory drugs. T cell proliferative response to type II collagen (CII) in these patients with RA was assayed as previously, 9 and only 12 of the 22 PBMC samples responded positively to CII. T cell proliferative responses were considered positive if the stimulation index (ratio of bromodeoxyuridine (BrdU) incorporation in the presence of CII to BrdU incorporation in the absence of antigen) was .2. The CII non-responder PBMC samples were used as controls. Fibroblast-like synoviocyte (FLS) cultures were established in 10% FBS/DMEM from synovial tissue obtained from another nine unrelated patients with RA at time of knee replacement surgery. 12 Approval of the institutional human studies committee and individual informed consent from each subject were obtained before the initiation of the study.
Cell cultures
PBMCs (10 5 ) were cultured in duplicate with complete medium in the presence of phytohaemagglutinin (PHA, 1 mg/ml, Sigma, St Louis, Missouri, USA) or chicken CII (400 mg/ml, previously found as optimal concentration, Sigma) and with or without various numbers of hASCs (5610 4 to 2610 3 ) in flat-bottomed 96-well plates. Where indicated, hASCs (2610 4 ) were added to cocultures at different times after CII stimulation. In some experiments, T cells (10 5 ) isolated from RA PBMCs were cultured with CII (400 mg/ml) in the presence of APCs (2610 4 ) from the same donor and different numbers of allogeneic hASCs (5610 4 to 2610 3 ). In these cocultures, proliferative responses of APCs and hASCs were suppressed by pretreatment with mitomycin C (50 mg/ml, 30 min, Sigma) before being added to T cells. After 72-96 h culture, proliferation was evaluated by using a colourimetric method of BrdU incorporation (Roche, Basel, Switzerland). Cytokine contents were determined as below. To determine the cell-contact dependence of the suppressive response, we placed CIIstimulated PBMC (10 5 ) in the lower insert of a transwell system (Millipore, 0.4 mm pore, Billerica, Massachusetts, USA), and hASCs (2610 4 ) in the upper well. After 96 h, PBMC proliferation in the lower compartment was determined. To produce supernatants from hASC cultures, hASCs (10 5 ) were stimulated for 24 h with tumour necrosis factor (TNF)a (20 ng/ ml) and interferon (IFN)c (200 ng/ml).
FLS (2610 5 ) were stimulated with lipopolysaccharide (LPS) (1 mg/ml, Sigma) or TNFa (20 ng/ml) in the presence or absence of hASCs (10 5 ). When indicated, FLS and hASCs were separated in a transwell system or coincubated in the presence of neutralising anti-interleukin 10 (IL10) antibodies (10 mg/ml, BD Bioscience, Erembodegem, Belgium). After 24-48 h, culture supernatants were assayed for cytokine contents and collagenase and gelatinase activities as described below. Prostaglandin E2 (PGE2) levels were determined using a competitive enzyme immunoassay kit (Cayman Chemical, Ann Arbor, Michigan, USA).
Cytokine determination
Cytokine levels in culture supernatants were determined by sandwich ELISAs using capture/biotinylated detection Abs from BD Pharmingen (Erembodegem, Belgium) following the manufacturer's recommendations. To identify whether hASCs selectively affected the production of cytokines on T cell subsets, intracellular cytokine contents were determined in CD4
+ and CD8 + T cells from patients with RA. hASCs and RA PBMCs were stimulated with CII (400 mg/ml) for 14 h, in the presence of monensin (1.33 mM, Sigma) for the last 6 h, and then stained with peridinin chlorophyll protein (PerCP) anti-CD4 or fluorescein isothiocyanate (FITC) anti-CD8 mAbs at 4uC, washed, fixed/permeabilised with Cytofix/Cytoperm solution (Becton Dickinson, Erembodegem, Belgium), stained with PE-conjugated anti-cytokine-specific mAbs (BD Pharmingen).
Flow cytometry
Cells were stained first for surface CD4 and CD25 with PerCP anti-CD4 and PE anti-CD25, fixed with Cytofix/Cytoperm solution (BD Pharmingen), incubated with FITC anti-cytotoxic T lymphocyte antigen 4 (CTLA4) or FITC anti-FoxP3 protein mAb diluted in 0.5% saponin, and analysed by flow cytometry (FACScalibur, BD Bioscience). The different CD4 
Gelatinase and collagenase activity determination
We used the EnzChek gelatinase/collagenase assay kit (Molecular Probes, Carlsbad, California, USA), a fibril degradation assay that utilises self-quenched fluorescein-conjugated gelatin and type I collagen, to determine the collagenase and gelatinase activity in cell-free supernatants.
Tr suppressive activity determination
To measure the suppressive capacity of T cells generated in the presence of hASC, T cells (T ASC ) were isolated from CIIactivated ASC-PBMC cocultures after 4 days by positive immunomagnetic selection with magnetic-bead-labelled anti-CD3 monoclonal antibodies (Miltenyi Biotec). Viable cells were recovered by density gradient centrifugation with Lymphoprep (Nycomed Pharma, Zurich, Switzerland), rested for 48 h in complete medium supplemented with IL2 (20 U/ml), and added at different ratios in a secondary culture to 10 5 PBMCs stimulated with CII (400 mg/ml) or with anti-CD3 Ab (5 mg/ ml). To investigate the antigen-dependent specificity these cells, the secondary cultures were performed with 10 5 T ASC and 2610 5 tetanus toxin (TT)-primed RA PBMCs in the presence of CII (400 mg/ml) or TT (1 mg/ml, AbD Serotec, Oxford, UK).
Statistical analysis
All results are expressed as mean (SD) and the Mann-Whitney U test was used to compare non-parametric data for statistical significance.
RESULTS
hASCs inhibit the activation of CII-specific CD4 and CD8 T cells from patients with RA
Recent studies have characterised the phenotype of hASCs and their immunoregulatory effects on T cells. 5 8 10 In this study, we investigated the ability of hASCs to inhibit the activation of PBMCs isolated from patients with RA. hASCs significantly inhibited the secretion of IFNc and the proliferation of PBMCs stimulated with PHA, a polyclonal mitogen ( fig 1A) . Importantly, hASCs dose-dependently decreased the proliferative response of PBMCs isolated from patients with RA that responded positively to CII, a major component of the hyaline cartilage ( fig 1B, upper panel) . A similar suppressive effect on the proliferative response was observed when allogeneic hASCs where added to cultures of CII-activated T cells and APCs ( fig 1B, bottom panel) . hASCs did not affect the survival and apoptosis of CII-reactive T cells (not shown). Noteworthy from a therapeutic point of view, delayed addition of hASCs significantly inhibited CII-stimulated T cell proliferation ( fig 1D) . Moreover, hASCs downregulated the production of the T helper (Th)1 cytokines IFNc and TNFa, as well as IL17 by CII-reactive T cells, whereas induced the secretion of the antiinflammatory cytokine IL10 ( fig 1E) . Probably because they lack 
class II MHCs (table 1), allogeneic ASCs did not contribute to T cell proliferation in the absence of antigenic stimulation (fig 1E). Intracellular cytokine staining in CD4
+ and CD8 + T cells analysed from the total PBMC population indicated that hASCs inhibited the production of IFNc and TNFa in both T cell subpopulations, while increasing the number of IL10-producing CD4 and CD8 T cells ( fig 1F) . hASC-mediated inhibition of CII-induced proliferation and IFNc, IL17 and TNFa production was partially reversed when PBMCs and hASCs were separated in transwell plates by a semipermeable membrane (fig 1E) , suggesting a cell-to-cell contact dependence. The partial involvement of soluble factors produced by hASCs on their immunosuppressive activity was supported by the fact that conditioned media from TNFa/IFNc-stimulated hASCs suppressed CII-induced PBMC activation ( fig 1E) .
hASCs deactivate the inflammatory response of monocytes and synovial cells from patients with RA Interestingly, we found that the hASC-induced production of IL10 by CII-reactive PBMCs was entirely cell-to-cell contact dependent ( fig 1E) . An initial cell contact between PBMCs and hASC seems to be enough to induce the secretion of IL10, even in the absence of CII stimulation ( fig 1E) . It has been recently demonstrated that BM-MSCs induce monocytes and dendritic cells (DCs) in a cell contact-dependent manner to secrete high IL10 amounts. 6 Therefore, we investigated whether hASCs stimulated IL10 production by monocytes. Monocytes isolated from patients with RA were LPS activated in the absence or presence of allogeneic hASCs. Neither monocytes nor hASCs produced significant IL10 levels when cultured alone, even in the presence of LPS; however, hASC-monocyte cocultures produced high amounts of IL10 through a cell to cell contactdependent mechanism (fig 2A) . Intracellular IL10 determination in the two cell populations showed that, once they enter into contact, IL10 expression is induced in hASCs and monocytes (fig 2A) . The involvement of IL10 was confirmed by the partial reversal of the inhibitory activity of hASCs on CII-induced RA T cell activation by neutralising anti-IL10 Abs ( fig 2B) .
We next investigated the capacity of hASCs to regulate the inflammatory response of the resident cells of the synovial membrane. hASC treatment of RA FLS cultures decreased the production of TNFa and PGE2, but not IL6, and reduced ) isolated from nine patients with RA were incubated with medium (unstimulated) or stimulated with lipopolysaccharide (LPS) (1 mg/ml) or tumour necrosis factor (TNF)a (20 ng/ml) in the presence or absence of hASCs (10 5 ). After 48 h, cytokine and prostaglandin E2 (PGE2) contents were determined in culture supernatants. After 24 h, culture supernatants were assayed for gelatinase and collagenase activities. *p,0.001 vs FLS alone. B. TNFa-activated or LPS-activated FLS and hASCs were separated in a transwell system or cocultured in the presence of neutralising anti-interleukin (IL)10 Abs. The levels of TNFa and PGE2, and the collagenase activity were determined in culture supernatants. Results are expressed as the inhibitory activity of hASCs on activated FLS.ˆp,0.001 vs hASC-treated FLS without anti-IL10 Abs or transwell plates. TNFa (fig 3A) . The inhibitory effects were cell-tocell contact and IL10 dependent ( fig 3B) .
hASCs induce antigen-specific Tr in PBMCs from patients with RA
Numerous sources indicate that Tr cells play a critical role in the maintenance of self-immune tolerance in RA. 1 3 The observed downregulation of the CII-reactive Th1 response, together with the elevated levels of the regulatory cytokine IL10, prompted us to investigate the suppressive activity of T cells generated in the presence of hASCs (T ASC ) on the activation of effector T cells from patients with RA. In contrast to T control cells, T ASC cells suppressed the proliferation of and IFNc production by CIIactivated RA PBMCs (fig 4A) . This effect was significantly reversed by anti-IL10 Abs ( fig 4B) . As expected, IL2 bypassed the suppressive activity of T ASC cells (fig 4B) . This suppressive effect was antigen specific, because T ASC neither inhibited the proliferative response of RA PBMCs activated with anti-CD3 Abs ( fig 4A) or prevented TT-induced activation in TT-primed RA PBMCs (fig 4C) . Flow cytometry analysis of T ASC cells showed increased percentages of CD4 + CD25 high T cells expressing the Tr markers/mediators CTLA4 and FoxP3 protein ( fig 4D) . Addition of the different T cell populations generated by hASCs to CII-activated T cell cultures demonstrated that the suppressive activity of the T ASC cells mainly resides in the CD4 + CD25 high T cell population ( fig 4E) .
DISCUSSION
A desirable therapeutic approach for RA should prevent inflammatory and autoimmune components of the disease. In this study, we demonstrated that adult mesenchymal stem cells isolated from adipose tissue exert profound suppressive responses on CII-reactive T cells from patients with RA in various ways: they suppress CII-induced T cell proliferation, inhibit the production of inflammatory cytokines by CD4 Th1 and CD8 Tc1 cells, stimulate the production of the antiinflammatory/suppressive cytokine IL10 by monocytes and T cells and induce the generation of antigen-specific Tr cells. Moreover, hASCs inhibit the production of inflammatory factors by activated synovial cells involved in the destruction of cartilage and bone in RA. Cell-based therapy for autoimmune disease with autologous haematopoietic stem cell transplants was initiated 12 years ago on over 700 patients with various severe autoimmune diseases. 13 Although this treatment was quite encouraging for systemic lupus erythematosus, systemic sclerosis and multiple sclerosis, achieving stable remission, most patients with RA showed only transient responses. This failure was most likely due to low dose conditioning regimens, resulting in too low a level of immunosuppression. Based on their ''immune privileged'' status, allogeneic healthy MSCs emerged as optimal substitutes in this therapy, resulting in more function seen in clinical settings. In agreement with our data, human BM-MSCs deactivated CII-reactive T cells isolated from blood and synovial fluid of allogeneic patients with RA. 9 However, an important issue for clinical translation of MSCs in RA is that their therapeutic use requires large quantities of cells for infusion. In this sense, large amounts of hASCs can be easily obtained from lipoaspirates of allogeneic healthy donors and rapidly expanded in vitro to generate a clinically effective dosage.
Before clinical translation, we must corroborate that hASCs maintain the immunosuppressive activity observed in vitro after their infusion in vivo. To this end, Djouad et al reported that an immortalised murine cell line derived from BM-MSCs did not confer any beneficial effect in a model of collagen-induced arthritis, while showing potent immunosuppressive actions in vitro, 14 suggesting that an inflammatory milieu could influence the immunoregulatory properties of MSCs. However, using the same experimental model, Augello et al described how the injection of primary allogeneic murine BM-MSCs at the disease onset significantly ameliorated arthritis signs. 7 This discrepancy could reside in the use of cell lines versus primary MSCs. Supporting the beneficial effect of MSCs in vivo, we recently demonstrated that hASCs and murine ASCs provided a highly effective therapy for experimental arthritis by strikingly reducing the two deleterious components of the disease (ie, the Th1-mediated autoimmune and inflammatory responses). 15 Of importance from a therapeutic point of view is the fact that hASCs efficiently ameliorated the clinical signs in mice with established arthritis. This correlates with the present work, showing the capacity of delayed administration of hASCs to still suppress CII-reactive RA PBMCs in ongoing cultures.
Several studies have reported that BM-MSCs and ASCs of murine origin downregulate the inflammatory and T cell responses in vitro and in vivo, involving very diverse mechanisms. 5-10 16-18 Our data demonstrate the participation of cell to cell contact and soluble factors in the deactivation of T cells by hASCs, where IL10 seems to play a critical role. IL10 involvement in the immunosuppressive action of BM-MSCs has been previously demonstrated. 19 20 Interestingly, hASCs mainly produce IL10 after their interaction with monocytes, and this cell-cell contact also commits monocytes to produce IL10 in high amounts. In agreement, others have described how BM-MSCs stimulate IL10 production by monocytes and DCs. 6 19 21 Therefore, the possibility exists that hASCs indirectly suppress T cell activation by increasing the production of IL10 by APCs. By contrast, a recent study identified TGFb1 as a critical mediator involved in the suppressive response of human BM-MSCs on CII-activated PBMCs. 9 However, TGFb1 blockade did not significantly affect the immunomodulatory action of hASCs (data not shown), suggesting that hASCs and BM-MSCs different numbers to PBMCs isolated from the same patient and stimulated with CII (400 mg/ml) or anti-CD3 Abs (5 mg/ml). The proliferative response and interferon (IFN)c levels were determined. n = 8. *p,0.001 vs CII-activated PBMC in the absence of T ASC . B. Interleukin (IL)2 (50 U/ml), neutralising anti-IL10 or anti-transforming growth factor (TGF)b1 Abs (10 mg/ml) or isotype control Abs were added to CII-stimulated PBMC-T ASC cocultures (at a ratio of 2:1), and the proliferative response determined after 4 days. n = 8. could act through different suppressive mechanisms. Alternatively, hASCs could be interfering with the function of the APCs and subsequent T cell activation. However, the fact that hASCs suppressed cell proliferation induced by a T cell mitogen argues against this hypothesis.
By contrast, we demonstrated that the induction of IL10-secreting T cells with antigen-specific regulatory capacity could significantly contribute to the suppressive activity of hASCs on RA T cells. hASC-induced Tr cells specifically suppress CII-driven responses, but not other responses to unrelated antigens, such as TT, or to polyclonal activation. Phenotypic characterisation of these cells showed that hASCs induced the emergence of CD4 +
CD25
high expressing the transcription factor FoxP3, a phenotypic Tr marker, and the immunosuppressive molecule CTLA4. 1 As described for other inducible Tr, 1 IL10 seems to play a crucial role in the suppressive capacity of the hASC-induced Tr. Other authors previously reported that BM-MSCs directly induce CD4 and CD8 Tr functions in allogeneic systems. 22 23 Although our study could be the first describing the induction of antigenspecific suppressive T cells by human MSCs of any origin, other reports described the capacity of murine MSCs to suppress antigen-specific T cell responses, 7 15 16 and human MSCs to inhibit anti-antigen-driven T cell activation. 24 25 Regarding the mechanism involved, it is still unknown whether hASCs act directly on T cells inducing de novo generation of Tr or the expansion of existing naturally occurring Tr. We recently described that hASCs can convert in the periphery of arthritic animal antigen-primed CD4 +
2 cells to CD4 + CD25 + Tr, 15 supporting de novo generation of Tr by hASCs. TGFb1 and IL10 have been critically involved in the peripheral generation of CD4 + CD25 + Tr. 1 Whereas TGFb1 was not significantly augmented in the hASCs and RA PBMCs cocultures, the production of IL10 did dramatically increase. Therefore, the ASC-induced IL10 secretion could participate in the Tr induction. Alternatively, BM-MSCs alter the differentiation and activation of DCs, inducing the generation of tolerogenic DCs with capacity to generate Tr. 21 The hypothesis of induction of APCs with tolerogenic activity by hASCs emerges as an attractive mechanism that needs further investigation, and it will partially explain the antigen-specific nature in the action of the hASC-induced Tr.
We envision that once the benefits and risks associated with the injection of hASCs are well defined, the use of hASCs opens new therapeutic perspectives for a cell-based therapy of autoimmune/inflammatory diseases. The capacity of hASCs to regulate various inflammatory mediators, and suppress Th1-type responses through the generation of Tr, might offer a therapeutic advantage over existing therapies directed against a single mediator. However, because RA is of unknown aetiology and CII is not absolutely established as an autoantigen, 9 26 27 precautions should be taken before considering translatable clinical application of hASCs to RA from our results.
